- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00329836
A Research Study to Examine Cutaneous Allodynia and Cluster Headache
February 9, 2025 updated by: Stephen D. Silberstein, Thomas Jefferson University
This is a research study examining cutaneous allodynia and cluster headaches.
Cutaneous allodynia means the feeling of pain or unpleasant sensation when normally non-painful stimuli (e.g.
light touch) are applied to the skin.
Many studies have been performed looking at the presence of cutaneous allodynia in patients with migraines; however, few studies have examined it in cluster headache patients.
There is still much to be learned about the brain and how it functions if the investigators are to understand the underlying causes of cluster headache.
It is important to explore cutaneous allodynia in cluster headache as it may help guide physicians with the care of these individuals.
Sixty patients will be screened for this study.
Thomas Jefferson University is the only center enrolling patients in this research study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
41
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Jefferson Headache Center/ Thomas Jefferson University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Subjects with cluster headache
Description
Inclusion Criteria:
- Male and female patients aged 18-75, inclusive
- Diagnosis of cluster headache, episodic or chronic.
- Patients with episodic CH can be either in active cluster period or not.
- Ability to read and understand an informed consent form, where the study protocol is described.
Exclusion Criteria:
- Patients with abnormal sensory findings on examination, or any known neurological disease that may affect skin sensation (peripheral neuropathy, multiple sclerosis, stroke, etc).
- Patients who are cognitively impaired, as determined by investigator
- Patients with significant psychiatric disorder that may affect their understanding of the study protocol and/or their cooperation with the investigators.
- Patients who had taken an acute pain medication within 24 hours prior to allodynia testing.
- Patients with skin diseases that may cause abnormal skin sensation.
- Patients who had been treated with a nerve block in the 4 week period prior to allodynia testing
- Patients who had been treated with Botulinum neurotoxin within the 4 month period prior to allodynia testing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Subjects with cluster headache
Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
|
Other: There are no interventions in the observational study. The symptom of allodynia was measured.
No intervention.
Description of allodynia testing appears elsewhere in this document
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of Allodynia in Subjects With Cluster Headache
Time Frame: Allodynia was assessed at the screening visit
|
Allodynia (discomfort to normal sensation) was assessed by brushing at constant rate of 2 brushes/sec and pressure allodynia with Von Frei hairs.
Outcome (discomfort) was measured on a 100 mm visual analogue scale.
|
Allodynia was assessed at the screening visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Abraham A. Ashkenazi, M.D., Jefferson Headache Center/ Thomas Jefferson University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
May 24, 2006
First Submitted That Met QC Criteria
May 24, 2006
First Posted (Estimated)
May 25, 2006
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 9, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA/CH/01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cluster Headache
-
Diamond Headache ClinicGlaxoSmithKlineUnknownEpisodic Cluster Headache | Chronic Cluster HeadacheUnited States
-
Eli Lilly and CompanyCompletedEpisodic Cluster Headache | Chronic Cluster HeadacheSpain, United States, Finland, Germany, United Kingdom, Belgium, France, Denmark, Italy, Netherlands, Canada, Greece
-
Salvia BioElectronicsActive, not recruitingChronic Cluster HeadacheAustralia
-
Salvia BioElectronicsRecruitingChronic Cluster HeadacheNetherlands
-
Winston LaboratoriesNot yet recruitingEpisodic Cluster Headache
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedChronic Cluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Eli Lilly and CompanyCompletedChronic Cluster HeadacheUnited States, Germany, France, Canada, Belgium, Denmark, Finland, Greece, Italy, Netherlands, Spain, United Kingdom
-
University of Roma La SapienzaCompletedChronic Cluster HeadacheItaly
-
University of LiegeCompletedChronic Cluster HeadacheBelgium
-
Autonomic Technologies, Inc.CompletedChronic Cluster Headache
Clinical Trials on There are no interventions in the observational study. The symptom of allodynia was measured.
-
Maastricht University Medical CenterRecruiting
-
European Society of CardiologyRecruitingSpontaneous Coronary Artery DissectionDenmark, Netherlands, United Kingdom, France, Belgium, Austria, Cyprus, Spain, Iran, Islamic Republic of, Portugal, Italy, Czech Republic, Singapore, Argentina, Bosnia and Herzegovina, Brazil, Croatia, Germany, Greece, New Zealand and more
-
Tempus AIRecruitingBreast Cancer | Early Stage Breast Cancer | TNBC - Triple-Negative Breast Cancer | HER2 + Breast Cancer | HR Positive/HER-2 Negative Breast CancerUnited States
-
Centro Cardiologico MonzinoCompletedDepression | Quality of Life | Anxiety | Emotional Stress | Self-care | Chronic Cardiovascular DiseaseItaly
-
Shenzhen Center for Disease Control and PreventionCompletedPuberty, Precocious
-
Union Hospital, Tongji Medical College, Huazhong...Not yet recruitingShock | Acute Respiratory Distress SyndromeChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruiting
-
Spineology, IncCompletedLumbar Degenerative Disc DiseaseUnited States
-
BG Trauma Center TuebingenCompletedHand InfectionsGermany